Skip to content
The Intraday Markets
Pulse

Briefings

Morning BriefOvernight tape and the setup for the openMid-Morning UpdateWhat changed after the opening bell

Markets

Market DashboardTape, movers, watchlist, and cross-asset contextPre-Market SheetOvernight setup, futures, and early moversGlobal SessionsInternational clocks and index performanceInsider ActivityLatest reported executive transactions

ICLR Research

Price ChartTechnical charting and drawing workspaceFundamentals ChartCompare financial metrics across timeCompany OverviewA visual snapshot of company performanceFinancial StatementsPrice, filings, key statistics, and news

Newsletter

Morning Production ReportRanked stories, charts, and newsletter readiness

Financial Statements

Explore

Markets, briefings, and company research

ICLR
Pulse

Briefings

MorningMid-Morning

Markets

DashboardPre-MarketGlobalInsiders

ICLR Research

ChartFundamentalsOverviewFinancials

Newsletter

Morning Report

Newsletter operations and account tools are available from your profile menu after sign-in.

ICLR

$163.15
$-4.18 (-2.50%)-2.50%
Closed
Loading chart...
IndexN/A
Market Cap12.49B
Enterprise Value17.20B
Income$0.15B
Sales$2.00B
EmployeesN/A
P/E13.31
P/S1.73
P/B1.55
P/C16.58
EV/EBITDA20.88
EV/SalesN/A
EPS (ttm)12.26
EarningsN/A
Gross Margin26.37%
Oper. Margin12.27%
Profit Margin2.78%
Volume0.32M
Shs Outstand0.08B
Change-2.59%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
Income Statement by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Revenue$8.28B$8.12B$7.74B$5.48B$2.80B$2.81B$2.60B$1.76B
Cost of Revenue$5.85B$5.72B$5.53B$3.97B$1.99B$1.97B$1.83B$1.03B
Gross Profit$2.44B$2.40B$2.21B$1.51B$808.03M$831.70M$769.49M$726.96M
Gross Margin29.42%29.56%28.60%27.52%28.89%29.64%29.64%41.34%
Operating Expenses$1.34B$1.44B$1.42B$1.13B$416.53M$398.30M$396.13M$388.63M
Operating Income$1.10B$956.15M$795.24M$378.53M$391.50M$433.41M$373.36M$338.34M
Operating Margin13.26%11.78%10.27%6.91%14.00%15.45%14.38%19.24%
Net Income$791.47M$612.34M$505.30M$153.19M$327.81M$373.99M$322.82M$281.49M
Net Margin9.56%7.54%6.53%2.79%11.72%13.33%12.44%16.01%
EPS (Basic)$9.60$7.46$6.20$2.28$6.29$6.85$5.96$5.20
EBITDAN/AN/AN/AN/AN/AN/AN/AN/A
Stock Option Compensation ExpenseN/AN/AN/AN/AN/AN/AN/AN/A
Price To Earnings RatioN/AN/AN/AN/AN/AN/AN/AN/A
Price To Sales RatioN/AN/AN/AN/AN/AN/AN/AN/A
Shares OutstandingN/AN/AN/AN/AN/AN/AN/AN/A
Market CapitalizationN/AN/AN/AN/AN/AN/AN/AN/A
Balance Sheet by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Cash & Short Term InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Short Term ReceivablesN/AN/AN/AN/AN/AN/AN/AN/A
InventoriesN/AN/AN/AN/AN/AN/AN/AN/A
Other Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Net Property, Plant & EquipmentN/AN/AN/AN/AN/AN/AN/AN/A
Total Investments and AdvancesN/AN/AN/AN/AN/AN/AN/AN/A
Long-Term Note ReceivableN/AN/AN/AN/AN/AN/AN/AN/A
Intangible AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Other AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Assets$16.88B$16.99B$17.19B$17.39B$3.44B$2.91B$2.35B$2.19B
Short Term Debt Incl. Current Port. of LT DebtN/AN/AN/AN/AN/AN/AN/AN/A
Accounts PayableN/AN/AN/AN/AN/AN/AN/AN/A
Income Tax PayableN/AN/AN/AN/AN/AN/AN/AN/A
Other Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Provision for Risks ChargesN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Other LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Liabilities$7.35B$7.75B$8.69B$9.32B$1.59B$1.29B$999.97M$955.62M
Non-Equity ReservesN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Stock - Carrying ValueN/AN/AN/AN/AN/AN/AN/AN/A
Common EquityN/AN/AN/AN/AN/AN/AN/AN/A
Total Shareholders Equity$9.52B$9.24B$8.50B$8.07B$1.85B$1.62B$1.35B$1.19B
Accumulated Minority InterestN/AN/AN/AN/AN/AN/AN/AN/A
Total Equity$9.52B$9.24B$8.50B$8.07B$1.85B$1.62B$1.35B$1.19B
Total Liabilities & Stockholders Equity$16.88B$16.99B$17.19B$17.39B$3.44B$2.91B$2.35B$2.19B
Book Value Per ShareN/AN/AN/AN/AN/AN/AN/AN/A
Tangible Book Value Per ShareN/AN/AN/AN/AN/AN/AN/AN/A
Full-Time EmployeesN/AN/AN/AN/AN/AN/AN/AN/A
Price to Book RatioN/AN/AN/AN/AN/AN/AN/AN/A
Return on AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Return on EquityN/AN/AN/AN/AN/AN/AN/AN/A
Return on Invested CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Quick RatioN/AN/AN/AN/AN/AN/AN/AN/A
Current RatioN/AN/AN/AN/AN/AN/AN/AN/A
Cash Flow by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Net Income$791.47M$612.34M$505.30M$153.19M$327.81M$373.99M$322.82M$281.49M
DepreciationN/AN/AN/AN/AN/AN/AN/AN/A
Other Funds (Non Cash)N/AN/AN/AN/AN/AN/AN/AN/A
Funds from OperationsN/AN/AN/AN/AN/AN/AN/AN/A
Extraordinary ItemN/AN/AN/AN/AN/AN/AN/AN/A
Changes in Working CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Income Taxes PayableN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Operating Activities$1.29B$1.16B$563.32M$829.14M$594.72M$412.54M$264.01M$48.74M
Capital ExpendituresN/AN/AN/AN/AN/AN/AN/AN/A
Net Assets From AcquisitionsN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Fixed Assets and BusinessesN/AN/AN/AN/AN/AN/AN/AN/A
Purchase or Sale of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Purchase of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Sale Or Maturity of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Other UsesN/AN/AN/AN/AN/AN/AN/AN/A
Other SourcesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Investing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Cash Dividends PaidN/AN/AN/AN/AN/AN/AN/AN/A
Change in Capital StockN/AN/AN/AN/AN/AN/AN/AN/A
Repurchase of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Proceeds from Stock OptionsN/AN/AN/AN/AN/AN/AN/AN/A
Issuance or Reduction of Debt, NetN/AN/AN/AN/AN/AN/AN/AN/A
Change in Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Issuance of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Reduction of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Net Financing Active Other Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Other Financing Activities UsesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Financing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Exchange Rate EffectN/AN/AN/AN/AN/AN/AN/AN/A
Net Change in CashN/AN/AN/AN/AN/AN/AN/AN/A
Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Dividends (Cash Flow)N/AN/AN/AN/AN/AN/AN/AN/A
Price to Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A

Company coverage

Latest news

20 stories
Aug 5 · 4:30AM[Latest] Global eClinical Solutions Market Size/Share Worth USD 42.55 Billion by 2035 at a 13.98% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)GlobeNewswire Inc. ↗Jul 15 · 10:46AMGlobal Clinical Trials Market to Reach $176.32 Billion by 2030 as AI and Decentralized Research Accelerate GrowthGlobeNewswire Inc. ↗Jul 9 · 8:51PMINVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in ICON plc (ICLR) to Contact Law FirmGlobeNewswire Inc. ↗Jun 24 · 9:02PMWhy Icon Stock Crushed it on WednesdayThe Motley Fool ↗Jun 22 · 7:30PMGlobal Decentralized Clinical Trials Market Size/Share Worth USD 38.3 Billion by 2035 at a 14.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)GlobeNewswire Inc. ↗Apr 24 · 9:53AMClinical Trial Data Visualization Research Report 2026: $1.82 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FGlobeNewswire Inc. ↗Apr 24 · 8:51AMeCOA, eSource and Clinical Trials Research Report 2026: $81.46 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FGlobeNewswire Inc. ↗Feb 20 · 1:00AMICLR SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws ViolationsGlobeNewswire Inc. ↗
Show 12 more stories↓
Feb 18 · 3:10PMFDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck CancerBenzinga ↗Feb 18 · 3:00PMClinical Trials Support Software Solutions in a $34.15B Trial Economy by 2035GlobeNewswire Inc. ↗Feb 17 · 7:30PMGEMI ALERT: Gemini Space Station Shareholders Should Contact Block & Leviton To Potentially Recover LossesGlobeNewswire Inc. ↗Feb 12 · 12:38PMClinical Research Provider Icon Stock Crashes On Accounting ProbeBenzinga ↗Jan 27 · 7:12PMTrinity Street Sells $22 Million of Axalta Coating Systems StockThe Motley Fool ↗Oct 1 · 2:00PMReal World Evidence Solutions Research and Forecast Report 2025-2030: Growth Opportunities in Emerging Markets and Increased Focus on End-To-End Rwe Services, & Personalized and Precision MedicineGlobeNewswire Inc. ↗Jul 24 · 6:01PMICON Stock Up After Q2 Results Signal Growing Confidence In Biopharma RecoveryBenzinga ↗Jun 5 · 8:57AMRegulatory Affairs Outsourcing Market Analysis Report 2025: Globalization of Biopharmaceutical and Medical Device Companies Bolster Growth - Trends, Opportunities, and Forecasts 2020-2030GlobeNewswire Inc. ↗Apr 6 · 12:20PMFaruqi & Faruqi Reminds ICON Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 11, 2025 - ICLRGlobeNewswire Inc. ↗Apr 3 · 10:13PMAnne Whitaker Appointed as Non-Executive DirectorGlobeNewswire Inc. ↗Apr 2 · 2:22AMICON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ICON plc - ICLRGlobeNewswire Inc. ↗Apr 1 · 6:19PMICLR DEADLINE: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages ICON plc Investors to Secure Counsel Before Important April 11 Deadline in Securities Class Action – ICLRGlobeNewswire Inc. ↗

Insider Trading

View All
Insider
Type
Shares
Price
Value
Date
CIARAN MURRAY
Sell
2.7K
$164.29
$440K
Aug 11, 26
NIGEL CLERKIN
Sell
2.3K
$164.29
$372K
Aug 11, 26
JULIE ANN O'NEILL
Sell
915
$164.29
$150K
Aug 11, 26
RONAN MARTIN MURPHY
Sell
841
$164.29
$138K
Aug 11, 26
JOHN CLIMAX
Sell
841
$164.29
$138K
Aug 11, 26

Company

CEO: Barry BalfeEmployees: 40200www.iconplc.com
About the company↓

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Discover more

You may be interested in
JPM

JPMorgan Chase & Co

$362.84

↓ 0.14%
NFLX

Netflix Inc

$78.16

↑ 0.11%
V

Visa Inc

$364.15

↓ 0.33%
DIS

Walt Disney Co

$106.85

↑ 2.10%
IBM

IBM Corp

$234.32

↓ 1.01%
TSLA

Tesla Inc

$342.27

↑ 0.49%
BAC

Bank of America Corp

$64.49

↑ 0.61%
ORCL

Oracle Corp

$150.52

↓ 3.49%
NVDA

NVIDIA Corp

$225.16

↓ 0.24%
MA

Mastercard Inc

$569.29

↑ 0.40%
INTC

Intel Corp

$102.50

↓ 1.43%
AMZN

Amazon.com Inc

$262.65

↓ 0.75%
The Intraday Markets

© 2026 The Intraday. All rights reserved.

Market data may be delayedFor informational purposes onlyFMP · Massive · SEC